Analysis of the latest medical insurance prices and reimbursement policies for Lynparza/Olaparib in 2025

Olaparib has been approved for marketing in China and has been included in Class B medical insurance, providing reimbursement support for patients with specific indications. The implementation of this policy has brought new treatment options to some cancer patients, allowing them to better cope with the high cost of drugs.

Olaparib's Medicare reimbursement policy is limited to specific indications, which include treatment-naïve patients with germline or somaticBRCA-mutated advanced epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. Patients who achieve complete remission or partial remission after receiving first-line platinum-based chemotherapy can obtain maintenance treatment through Medicare. In addition, patients with homologous recombination repair deficiency (HRD)-positive advanced epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer are also eligible for medical insurance after treatment with platinum-containing chemotherapy combined with bevacizumab. Finally, olaparib is also included in the reimbursement scope for patients with metastatic castration-resistant prostate cancer who carry BRCA mutations and have failed previous treatments.

In terms of price, the common specifications of Lynparza in the domestic market include100mg 7 tablets and 8 tablets and 150mg 56 tablets, with each box selling for around RMB 6,000. Although this price is relatively high for patients, the coverage of medical insurance policies relieves patients from certain financial pressure when shouldering the cost of drugs. However, the specific reimbursement ratio and payment method still need to be determined according to the specific provisions of local medical insurance policies.

In addition, generic drugs of Lynparza also exist in overseas markets. These generic drugs are generally more affordable and can provide patients with choices. For example, the ingredients of generic drugs produced in countries such as Laos and Bangladesh are basically the same as those of the original drugs. Taking the specification of 112 tablets of 50mg as an example, each box sells for about more than 2,000 yuan. This price advantage makes some patients more likely to choose generic drugs, especially when financial conditions are limited.

Reference materials:https://www.lynparza.com/